Abstract 1366P
Background
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) inhibitor, has been the standard of care for untreated and previously treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The common adverse events (AEs) of lorlatinib leading to drug discontinuation or dose reduction were hyperlipidemia, edema, and central nervous system (CNS)/ psychiatric disorders. The association between AEs and serum concentrations of lorlatinib remains unclear.
Methods
We retrospectively reviewed advanced ALK-positive NSCLC patients treated with lorlatinib between December 2018 and July 2022. The association between AEs and serum concentrations of lorlatinib was assessed at 28 days (± 14 days) after the initiation of lorlatinib using a high-performance liquid chromatography tandem mass spectrometry.
Results
Among 55 eligible patients, the median age was 54 years (range: 23–79) and the median number of treatment lines was 2 (range: 2-10). Most patients were female (29 [53%]) and performance status 0-1 (48 [87%]). Grade 3 or higher AEs occurred in 23 patients (42%) including hyperlipidemia in 18 (33%), edema in 5 (9%), and CNS/ psychiatric disorders in 4 (7%). Discontinuation or dose reduction was required in 21 patients (38%). Serum concentrations were measured in 36 patients (65%) and were significantly higher in the patients experiencing grade 3 or higher AEs than those without (462 ng/mL vs 177 ng/mL, p<0.01). On the other hand, there was no significant difference in progression-free survival (PFS) between the patients who had experienced the discontinuation or dose reduction within the first 6 months and those who had not (12.8M vs 5.2M, p=0.14).
Conclusions
The incidence of grade 3 or higher AEs with lorlatinib was associated with high serum concentrations at the first month of treatment. Drug discontinuation or dose reduction had no impact on PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yoshida: Financial Interests, Personal and Institutional, Research Grant, Personal fees: Amgen, AstraZeneca, Ono, MSD, Novartis, Chugai, BMS; Financial Interests, Institutional, Research Grant: Takeda, Daiichi Sankyo, AbbVie; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Taiho, Lilly, Roche, ArcherDX. Y. Matsumoto: Financial Interests, Institutional, Research Grant: National Cancer Center Research and Development Fund, Grant-in-Aid for Scientific Research on Innovative Areas, Hitachi, Ltd; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Olympus; Financial Interests, Personal, Speaker’s Bureau, Personal fees: AstraZeneca, Novartis, Cook, Amco Inc, Thermo Fisher Scientific, Erbe Elektromedizin GmbH, Fujifilm, Chugai, Eli Lilly. Y. Shinno: Financial Interests, Personal, Speaker’s Bureau, Personal fees: BMS, Chugai, AstraZeneca, Eli Lilly; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Ono; Financial Interests, Institutional, Research Grant: Janssen, Japan Clinical Research Operations K.K. Y. Okuma: Financial Interests, Institutional, Research Grant: Roche, AbbVie K.K; Financial Interests, Personal, Speaker’s Bureau, Personal fees: AstraZeneca, EIi Lilly K.K, Bristol Myers Squibb, Pfizer, Taiho Pharma Co. Ltd., AstraZeneca, Nippon, Boehringer Ingelheim, Chugai Pharma Co. Ltd., Ono Pharma Co. Ltd., Taiho Pharma Co. Ltd.. Y. Goto: Financial Interests, Institutional, Research Grant: AZK, AbbVie, Kyorin, Preferred Network; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Pfizer, Eli Lilly, Bristol Myers Squibb, Ono, Novartis, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Chugai, Taiho, Boehringer Ingelheim, MSD, Merck, Thermo Fischer, AstraZeneca, Chugai, Guardant Health Inc., Illumina. H. Horinouchi: Financial Interests, Personal and Institutional, Research Grant, Personal fees: MSD, AstraZeneca, BMS, Ono, Chugai, Roche, Novartis; Financial Interests, Institutional, Research Grant: AbbVie, Merck Biophama, Daiichi Sankyo, Janssen, Genomic Health; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Eli Lilly, Kyowa-Kirin. N. Yamamoto: Financial Interests, Personal and Institutional, Research Grant, Personal fees: Chugai, Eisai, Lilly, BMS, Pfizer, Boehringer Ingelheim, Ono Pharmaceutical Co., Ltd, Takeda, Otsuka; Financial Interests, Institutional, Research Grant: Taiho, Quintiles, Astellas, Novartis, Daiichi Sankyo, Kyowa-Hakko Kirin, Bayer, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc., Carna Biosciences, Genmab, Shionogi; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Sysmex, AstraZeneca, Cimic. Y. Ohe: Financial Interests, Personal and Institutional, Research Grant, Personal fees: AstraZeneca, Chugai, Eli Lilly, Ono, BMS, Kyorin, Pfizer, Taiho; Financial Interests, Institutional, Research Grant: Dainippon-Sumitomo, Novartis, Takeda, Kissei, Daiichi Sankyo, Janssen, Loxo; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Boehringer Ingelheim, Bayer, MSD, Nippon Kayaku, Kyowa Hakko Kirin, Celltrion, Amgen, An Heart Tharapeutics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1068P - Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
Presenter: Salvatore Cortellino
Session: Poster session 19
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19